Trial Profile
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Entospletinib (Primary) ; Cytarabine; Dexamethasone; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 12 Nov 2019 Status changed from completed to discontinued.
- 25 Dec 2018 Status changed from active, no longer recruiting to completed.
- 05 Oct 2018 Planned End Date changed from 1 Sep 2021 to 1 Dec 2018.